Results 231 to 240 of about 143,702 (317)

Organ donation from extracorporeal membrane oxygenation and ventricular assist devices in Victoria, Australia: Characteristics and trends. [PDF]

open access: yesCrit Care Resusc
Nainani VK   +7 more
europepmc   +1 more source

Charting the Course for Careers in Interventional Heart Failure: Training, Challenges, and Future Directions. [PDF]

open access: yesJ Soc Cardiovasc Angiogr Interv
Cheng R   +10 more
europepmc   +1 more source

The tacrolimus concentration‐to‐dose ratio is associated with kidney function in heart transplant recipients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Heart transplantation (HT) is frequently complicated by chronic kidney disease, of which tacrolimus‐related nephrotoxicity is an important cause. In kidney and liver transplant recipients, fast tacrolimus metabolism (defined as a low concentration‐to‐dose [C0/D] ratio), negatively affects kidney function.
Maaike R. Schagen   +9 more
wiley   +1 more source

New Developments in Cardiac Assist Devices

open access: yesCleveland Clinic Journal of Medicine, 1987
Z. N. Zakov, R. W. Stewart
openaire   +2 more sources

Radial Artery Tonometry to Determine Cardiac Output in Left Ventricular Assist Device Patients: A Comparison with Transthoracic Echocardiography

open access: hybrid, 2018
Rashad Zayat   +8 more
openalex   +1 more source

Comparison of mechanical resuscitation by an LV Impella device to extracorporeal resuscitation using VAECMO in a large animal model. [PDF]

open access: yesSci Rep
Billig S   +8 more
europepmc   +1 more source

Artificial intelligence‐assisted design, synthesis and analysis of smart biomaterials

open access: yesBMEMat, EarlyView.
Smart biomaterials are rapidly emerging as tools for tissue engineering, and artificial intelligence has played essential roles in biomaterial studies. By bridging the literature gap in AI‐based design, synthesis and analysis of smart biomaterials, the current review shares perspectives on how biomaterial scientists can practically incorporate AI for ...
Pengfei Jiang   +9 more
wiley   +1 more source

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

open access: yesCancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy